STOCK TITAN

[Form 4] Natera, Inc. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

In this Form 4, Natera director and co-founder Sheena Jonathan reported sales totaling 6,070 shares of Natera common stock: 3,070 shares on 08/08/2025 and 3,000 shares on 08/11/2025. The filing lists weighted-average prices for the 08/08 sales roughly in the mid-$156 to mid-$164 range and for the 08/11 sales roughly in the low-$150 to mid-$156 range. Footnotes state the 08/08 sales were executed under a Rule 10b5-1 plan adopted December 11, 2024, and the 08/11 sales were executed under a separate Rule 10b5-1 plan adopted June 7, 2024.

Following these transactions the reporting person retained 242,252 shares reported as directly owned and reported indirect trust holdings associated with Caraluna trusts in the ~34,282–35,662 share range across the trust entries. No derivative securities were reported.

Nel presente Form 4, la direttrice e cofondatrice di Natera, Sheena Jonathan, ha segnalato vendite per un totale di 6,070 azioni ordinarie di Natera: 3,070 azioni il 08/08/2025 e 3,000 azioni l'11/08/2025. Il deposito indica prezzi medi ponderati per le vendite dell'08/08 approssimativamente nella fascia medio-alta di $156–$164 e per quelle dell'11/08 approssimativamente nella fascia basso di $150–medio di $156. Le note precisano che le vendite dell'08/08 sono state eseguite nell'ambito di un piano Rule 10b5-1 adottato l'11 dicembre 2024, mentre le vendite dell'11/08 sono state eseguite nell'ambito di un piano Rule 10b5-1 separato adottato il 7 giugno 2024.

A seguito di queste operazioni, la persona che ha presentato la segnalazione ha mantenuto 242,252 azioni dichiarate come detenute direttamente e ha riportato partecipazioni indirette in trust legate ai Caraluna trust nella forchetta approssimativa di 34,282–35,662 azioni tra le voci dei trust. Non sono stati segnalati strumenti derivati.

En este Formulario 4, la directora y cofundadora de Natera, Sheena Jonathan, informó ventas por un total de 6,070 acciones ordinarias de Natera: 3,070 acciones el 08/08/2025 y 3,000 acciones el 11/08/2025. La presentación indica precios promedio ponderados para las ventas del 08/08 aproximadamente en el rango medio de $156 a medio de $164 y para las del 11/08 aproximadamente en el rango bajo de $150 a medio de $156. Las notas al pie señalan que las ventas del 08/08 se ejecutaron bajo un plan Rule 10b5-1 adoptado el 11 de diciembre de 2024, y que las ventas del 11/08 se ejecutaron bajo un plan Rule 10b5-1 separado adoptado el 7 de junio de 2024.

Tras estas operaciones, la persona informante mantuvo 242,252 acciones reportadas como propiedad directa y declaró participaciones indirectas en fideicomisos relacionadas con los Caraluna trusts en un rango aproximado de 34,282–35,662 acciones en las inscripciones de los fideicomisos. No se informaron valores derivados.

이 Form 4에서 Natera의 이사 겸 공동창업자 Sheena Jonathan은 Natera 보통주 총 6,070주를 매도했다고 보고했습니다: 2025/08/08에 3,070주, 2025/08/11에 3,000주. 제출서에는 08/08 매도분의 가중평균 가격이 대략 $156 중반~$164 중반 범위, 08/11 매도분은 대략 $150 초중반~$156 중반 범위로 기재되어 있습니다. 각주에는 08/08 매도는 2024년 12월 11일 채택된 Rule 10b5-1 계획에 따라 실행되었고, 08/11 매도는 2024년 6월 7일 채택된 별도의 Rule 10b5-1 계획에 따라 실행되었다고 명시되어 있습니다.

이 거래들 이후 보고인은 직접 보유로 보고된 242,252주를 유지했으며, Caraluna 트러스트와 관련된 간접 신탁 보유는 트러스트 항목별로 대략 34,282–35,662주 범위로 보고되었습니다. 파생증권은 보고되지 않았습니다.

Dans ce Formulaire 4, la directrice et cofondatrice de Natera, Sheena Jonathan, a déclaré des ventes totalisant 6,070 actions ordinaires de Natera : 3,070 actions le 08/08/2025 et 3,000 actions le 11/08/2025. Le dossier indique des prix moyens pondérés pour les ventes du 08/08 approximativement dans une fourchette milieu de $156 à milieu de $164, et pour celles du 11/08 approximativement dans une fourchette bas de $150 à milieu de $156. Les notes indiquent que les ventes du 08/08 ont été exécutées dans le cadre d'un plan Rule 10b5-1 adopté le 11 décembre 2024, et que les ventes du 11/08 ont été exécutées dans le cadre d'un plan Rule 10b5-1 distinct adopté le 7 juin 2024.

À la suite de ces opérations, la personne déclarant a conservé 242,252 actions déclarées comme détenues directement et a signalé des avoirs fiduciaires indirects liés aux trusts Caraluna dans une fourchette d'environ 34,282–35,662 actions selon les entrées des trusts. Aucun titre dérivé n'a été déclaré.

In diesem Formular 4 meldete die Natera-Direktorin und Mitgründerin Sheena Jonathan Verkäufe in Höhe von insgesamt 6,070 Aktien der Natera-Stammaktien: 3,070 Aktien am 08/08/2025 und 3,000 Aktien am 11/08/2025. Die Einreichung nennt gewichtete Durchschnittspreise für die Verkäufe vom 08/08 etwa im Bereich von mittleren $156 bis mittleren $164 und für die Verkäufe vom 11/08 etwa im Bereich von niedrigen $150 bis mittleren $156. Fußnoten geben an, dass die Verkäufe vom 08/08 im Rahmen eines am 11. Dezember 2024 angenommenen Rule-10b5-1-Plans ausgeführt wurden und die Verkäufe vom 11/08 im Rahmen eines separaten Rule-10b5-1-Plans vom 7. Juni 2024.

Nach diesen Transaktionen behielt die meldende Person 242,252 Aktien, die als direkt gehalten gemeldet wurden, und meldete indirekte Trust-Bestände im Zusammenhang mit den Caraluna-Trusts im Bereich von etwa 34,282–35,662 Aktien über die Trust-Einträge. Es wurden keine derivativen Wertpapiere gemeldet.

Positive
  • Sales were executed under pre-established Rule 10b5-1 trading plans, reducing concerns about opportunistic timing.
  • The reporting person retained 242,252 direct shares after the reported sales, indicating an ongoing ownership stake.
Negative
  • The reporting person disposed of 6,070 shares across the two reported dates, reducing direct holdings.
  • Some sales were executed indirectly through Caraluna 1 and Caraluna 2 trusts, which may complicate simple stake calculations for observers.

Insights

TL;DR: Insider sold 6,070 NTRA shares via pre-established 10b5-1 plans; retained direct stake remains material and the disclosures are routine.

The reported dispositions total 6,070 shares executed in multiple blocks on 08/08/2025 and 08/11/2025 at weighted-average prices shown per line. Sales on 08/08 were at higher weighted-average prices (approximately $156–$164) than many 08/11 blocks (approximately $149–$156). After the reported transactions the reporting person continued to hold 242,252 shares directly; additional indirect holdings are recorded in two Caraluna trusts. From a valuation standpoint these transactions appear to be scheduled plan sales rather than ad hoc liquidation and do not, by themselves, provide new operational information about Natera.

TL;DR: Use of Rule 10b5-1 plans supports governance transparency; filings are standard insider-sale disclosures without apparent governance concerns.

The Form 4 clearly discloses that the reported sales were effected under two separate Rule 10b5-1 trading plans, which typically reduce concerns about insider timing. The filing also reports indirect holdings held for beneficiaries of Caraluna trusts and includes the reporting person’s disclaimer of beneficial ownership over those trust-held shares. Disclosure appears complete for the transactions reported; there are no derivative transactions or amendments reflected in the form.

Nel presente Form 4, la direttrice e cofondatrice di Natera, Sheena Jonathan, ha segnalato vendite per un totale di 6,070 azioni ordinarie di Natera: 3,070 azioni il 08/08/2025 e 3,000 azioni l'11/08/2025. Il deposito indica prezzi medi ponderati per le vendite dell'08/08 approssimativamente nella fascia medio-alta di $156–$164 e per quelle dell'11/08 approssimativamente nella fascia basso di $150–medio di $156. Le note precisano che le vendite dell'08/08 sono state eseguite nell'ambito di un piano Rule 10b5-1 adottato l'11 dicembre 2024, mentre le vendite dell'11/08 sono state eseguite nell'ambito di un piano Rule 10b5-1 separato adottato il 7 giugno 2024.

A seguito di queste operazioni, la persona che ha presentato la segnalazione ha mantenuto 242,252 azioni dichiarate come detenute direttamente e ha riportato partecipazioni indirette in trust legate ai Caraluna trust nella forchetta approssimativa di 34,282–35,662 azioni tra le voci dei trust. Non sono stati segnalati strumenti derivati.

En este Formulario 4, la directora y cofundadora de Natera, Sheena Jonathan, informó ventas por un total de 6,070 acciones ordinarias de Natera: 3,070 acciones el 08/08/2025 y 3,000 acciones el 11/08/2025. La presentación indica precios promedio ponderados para las ventas del 08/08 aproximadamente en el rango medio de $156 a medio de $164 y para las del 11/08 aproximadamente en el rango bajo de $150 a medio de $156. Las notas al pie señalan que las ventas del 08/08 se ejecutaron bajo un plan Rule 10b5-1 adoptado el 11 de diciembre de 2024, y que las ventas del 11/08 se ejecutaron bajo un plan Rule 10b5-1 separado adoptado el 7 de junio de 2024.

Tras estas operaciones, la persona informante mantuvo 242,252 acciones reportadas como propiedad directa y declaró participaciones indirectas en fideicomisos relacionadas con los Caraluna trusts en un rango aproximado de 34,282–35,662 acciones en las inscripciones de los fideicomisos. No se informaron valores derivados.

이 Form 4에서 Natera의 이사 겸 공동창업자 Sheena Jonathan은 Natera 보통주 총 6,070주를 매도했다고 보고했습니다: 2025/08/08에 3,070주, 2025/08/11에 3,000주. 제출서에는 08/08 매도분의 가중평균 가격이 대략 $156 중반~$164 중반 범위, 08/11 매도분은 대략 $150 초중반~$156 중반 범위로 기재되어 있습니다. 각주에는 08/08 매도는 2024년 12월 11일 채택된 Rule 10b5-1 계획에 따라 실행되었고, 08/11 매도는 2024년 6월 7일 채택된 별도의 Rule 10b5-1 계획에 따라 실행되었다고 명시되어 있습니다.

이 거래들 이후 보고인은 직접 보유로 보고된 242,252주를 유지했으며, Caraluna 트러스트와 관련된 간접 신탁 보유는 트러스트 항목별로 대략 34,282–35,662주 범위로 보고되었습니다. 파생증권은 보고되지 않았습니다.

Dans ce Formulaire 4, la directrice et cofondatrice de Natera, Sheena Jonathan, a déclaré des ventes totalisant 6,070 actions ordinaires de Natera : 3,070 actions le 08/08/2025 et 3,000 actions le 11/08/2025. Le dossier indique des prix moyens pondérés pour les ventes du 08/08 approximativement dans une fourchette milieu de $156 à milieu de $164, et pour celles du 11/08 approximativement dans une fourchette bas de $150 à milieu de $156. Les notes indiquent que les ventes du 08/08 ont été exécutées dans le cadre d'un plan Rule 10b5-1 adopté le 11 décembre 2024, et que les ventes du 11/08 ont été exécutées dans le cadre d'un plan Rule 10b5-1 distinct adopté le 7 juin 2024.

À la suite de ces opérations, la personne déclarant a conservé 242,252 actions déclarées comme détenues directement et a signalé des avoirs fiduciaires indirects liés aux trusts Caraluna dans une fourchette d'environ 34,282–35,662 actions selon les entrées des trusts. Aucun titre dérivé n'a été déclaré.

In diesem Formular 4 meldete die Natera-Direktorin und Mitgründerin Sheena Jonathan Verkäufe in Höhe von insgesamt 6,070 Aktien der Natera-Stammaktien: 3,070 Aktien am 08/08/2025 und 3,000 Aktien am 11/08/2025. Die Einreichung nennt gewichtete Durchschnittspreise für die Verkäufe vom 08/08 etwa im Bereich von mittleren $156 bis mittleren $164 und für die Verkäufe vom 11/08 etwa im Bereich von niedrigen $150 bis mittleren $156. Fußnoten geben an, dass die Verkäufe vom 08/08 im Rahmen eines am 11. Dezember 2024 angenommenen Rule-10b5-1-Plans ausgeführt wurden und die Verkäufe vom 11/08 im Rahmen eines separaten Rule-10b5-1-Plans vom 7. Juni 2024.

Nach diesen Transaktionen behielt die meldende Person 242,252 Aktien, die als direkt gehalten gemeldet wurden, und meldete indirekte Trust-Bestände im Zusammenhang mit den Caraluna-Trusts im Bereich von etwa 34,282–35,662 Aktien über die Trust-Einträge. Es wurden keine derivativen Wertpapiere gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sheena Jonathan

(Last) (First) (Middle)
C/O NATERA, INC.
13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)
AUSTIN TX 78753

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) X Other (specify below)
CO-FOUNDER
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/08/2025 S 100(1) D $156.4042(2) 245,222 D
Common Stock 08/08/2025 S 301(1) D $158.6316(3) 244,921 D
Common Stock 08/08/2025 S 639(1) D $159.6754(4) 244,282 D
Common Stock 08/08/2025 S 1,030(1) D $162.7344(5) 243,252 D
Common Stock 08/08/2025 S 800(1) D $163.8838(6) 242,452 D
Common Stock 08/08/2025 S 200(1) D $164.5125(7) 242,252 D
Common Stock 08/11/2025 S 470(8) D $150.9526(9) 35,312 I By Caraluna 1 Trust(10)
Common Stock 08/11/2025 S 200(8) D $152.73 35,112 I By Caraluna 1 Trust(10)
Common Stock 08/11/2025 S 191(8) D $154.5986(11) 34,921 I By Caraluna 1 Trust(10)
Common Stock 08/11/2025 S 639(8) D $155.7951(12) 34,282 I By Caraluna 1 Trust(10)
Common Stock 08/11/2025 S 120(8) D $149.5642(13) 35,662 I By Caraluna 2 Trust(10)
Common Stock 08/11/2025 S 300(8) D $151.1217(14) 35,362 I By Caraluna 2 Trust(10)
Common Stock 08/11/2025 S 180(8) D $152.4(15) 35,182 I By Caraluna 2 Trust(10)
Common Stock 08/11/2025 S 270(8) D $154.0433(16) 34,912 I By Caraluna 2 Trust(10)
Common Stock 08/11/2025 S 610(8) D $155.7423(17) 34,302 I By Caraluna 2 Trust(10)
Common Stock 08/11/2025 S 20(8) D $156.32 34,282 I By Caraluna 2 Trust(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.36 to $156.45 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.26 to $159.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.28 to $160.01 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.22 to $163.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.29 to $164.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.44 to $164.59 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024.
9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.49 to $151.40 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.25 to $155.14 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
12. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.40 to $156.32 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
13. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.50 to $149.89 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
14. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.92 to $151.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
15. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.24 to $152.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
16. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.94 to $154.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
17. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.12 to $156.08 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Vincent Fontanilla, Attorney-in-Fact 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Sheena Jonathan report on the NTRA Form 4?

Sheena Jonathan reported sales of 6,070 Natera (NTRA) common shares: 3,070 on 08/08/2025 and 3,000 on 08/11/2025, in multiple blocks.

Were the insider sales executed under a trading plan for NTRA?

Yes. The 08/08 sales were effected under a Rule 10b5-1 plan adopted December 11, 2024, and the 08/11 sales were effected under a Rule 10b5-1 plan adopted June 7, 2024.

At what prices were the NTRA shares sold?

Reported weighted-average prices for the 08/08 blocks ranged approximately $156.36–$164.59 per share and for the 08/11 blocks approximately $149.50–$156.32 per share, per the filing footnotes.

How many NTRA shares does the reporting person own after these transactions?

Direct ownership reported at 242,252 shares after the transactions; indirect holdings associated with Caraluna trusts are reported in the ~34,282–35,662 range across trust entries.

Did the Form 4 report any derivative transactions for NTRA?

No derivatives were reported. Table II in the filing contains no derivative security entries.
Natera Inc

NASDAQ:NTRA

NTRA Rankings

NTRA Latest News

NTRA Latest SEC Filings

NTRA Stock Data

21.55B
131.84M
3.2%
96.66%
2.72%
Diagnostics & Research
Services-medical Laboratories
Link
United States
AUSTIN